SCHEMBL2472706

SCHEMBL2472706

COC(=O)[C@H]1CC[C@H](Oc2cccc(C)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.44
HCRTR2 O43614 2/20 0.44
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
LDHA P00338 1/20 0.40
DGAT1 O75907 1/20 0.39
TSHR P16473 1/20 0.39
ACSL1 P33121 2/20 0.39
BTK Q06187 1/20 0.38
GRM5 P41594 1/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
ALDH1A1 P00352 2/20 0.37
AXL P30530 1/20 0.37
TYRO3 Q06418 1/20 0.37
MERTK Q12866 1/20 0.37
PDE7A Q13946 1/20 0.37
HSD11B1 P28845 1/20 0.37
QPCT Q16769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2472710 1.00 HCRTR1 (0.44) HCRTR1HCRTR2HTR1ADRD2DRD4
SCHEMBL2473271 0.85 SMN1; SMN2 (0.43) ACSL1ALDH1A1QPCTQPCTLRAB9A
SCHEMBL2473274 0.85 SMN1; SMN2 (0.43) ACSL1ALDH1A1QPCTQPCTLRAB9A
SCHEMBL2476359 0.84 HCRTR1 (0.43) HCRTR1HCRTR2HTR1ADRD2DRD4
SCHEMBL2476361 0.84 HCRTR1 (0.43) HCRTR1HCRTR2HTR1ADRD2DRD4
SCHEMBL20909894 0.83 HCRTR1 (0.45) HCRTR1HCRTR2LDHATSHRGRM5
SCHEMBL21802698 0.80 MEN1 (0.44) ALDH1A1HSD11B1
SCHEMBL17868941 0.80 MEN1 (0.44) ALDH1A1HSD11B1
SCHEMBL30356808 0.79 EPHX2 (0.47) HCRTR1HCRTR2DGAT1ALDH1A1
SCHEMBL2469600 0.79 EPHX2 (0.47) HCRTR1HCRTR2DGAT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370441-B1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-09-11 EP disclosed
US-8461152-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES SCHNIDER PATRICK (CH) 2012-09-06 US disclosed
US-8227458-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
EP-2370441-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-10-05 EP disclosed
WO-2010060836-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES HOFFMANN-LA ROCHE, INC. 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 HCRTR1 72/4885HCRTR2 186/4885HTR1A 27/4885
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 HCRTR1 72/4885HCRTR2 186/4885HTR1A 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.